Focus: Catalent is a Contract Development and Manufacturing Organization (CDMO) serving pharma, biotech, and consumer health clients with manufacturing and formulation services. As a public company with 10,001–50,000 employees, it is a large-scale outsourced manufacturing partner headquartered in Somerset, NJ.
Profile data last refreshed 19h ago · AI intelligence enriched 2mo ago
Hot — 778 jobs added in 30d
Net +495 (778 new, 283 removed). Aggressive expansion phase.
4 recent layoff filings (12 mo) — 324 affected
Source: state DOL filings via Big Local News
Strong operational and manufacturing roles for process-minded professionals, but recent restructuring and post-acquisition instability warrant caution on long-term tenure and upside potential.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic anti-epileptic with established market; post-loss-of-exclusivity status indicates commodity revenue base.
Help build intelligence for Catalent
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Catalent's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Over-the-counter generic analgesic; limited differentiation or growth trajectory.
Established antihistamine generic; post-exclusivity with stable but non-growing demand.
Generic antihistamine in a crowded OTC segment; limited career growth driver.
1 discontinued, 0 duplicate formulations not shown
Catalent to sell UK facility to Codis in spray drying expansion - megaproject.com
Catalent to sell UK facility to Codis in spray drying expansion megaproject.com
Catalent sells UK facility to Codis; expands partnership with Nanoscope Therapeutics - Fierce Pharma
Catalent sells UK facility to Codis; expands partnership with Nanoscope Therapeutics Fierce Pharma
Codis Acquiring Catalent’s Nottingham UK Facility - Pulse 2.0
Codis Acquiring Catalent’s Nottingham UK Facility Pulse 2.0
The Changing Reality of Pharmaceutical Commercialization | PharmExec - Pharmaceutical Executive
The Changing Reality of Pharmaceutical Commercialization | PharmExec Pharmaceutical Executive
Codis To Acquire Catalent's Nottingham, UK Facility to Create Europe's Leading End-to-End Spray Dry Capability - PR Newswire
Codis To Acquire Catalent's Nottingham, UK Facility to Create Europe's Leading End-to-End Spray Dry Capability PR Newswire
Rezon Bio adds Catalent veteran to commercial team - The Pharma Letter
Rezon Bio adds Catalent veteran to commercial team The Pharma Letter
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Leveraging analytical and bioprocess platforms for biological product development and commercialization - A meeting report.
Validated GMP banking of a new set of genomically stable induced pluripotent stem cell lines using single-cell passaging.
Source: state DOL filings, aggregated via Big Local News
Sustained reduction-in-force activity over 16 months and stock delisting after 2023 acquisition create high structural risk; tenure security is uncertain despite current hiring.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo